Zomig - Instructions For Use, Price, Analogs, Reviews About Tablets

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Zomig

Zomig: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacodynamics and pharmacokinetics
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Zomig

ATX code: N02CC03

Active ingredient: Zolmitriptan (Zolmitriptan)

Manufacturer: Ltd. Astrazeneca, UK

Description and photo updated: 2019-30-07

Zomig is a drug with an anti-migraine effect.

Release form and composition

Zomig is produced in the form of film-coated tablets: yellow, biconvex, round, with "Z" engraving on one side (2 or 3 pcs. In blisters, 1 blister in a cardboard box).

The composition of 1 tablet includes:

• Active ingredient: zolmitriptan - 2.5 mg;
• Auxiliary components: anhydrous lactose - 100 mg, sodium carboxymethyl starch - 3 mg, microcrystalline cellulose - 15 mg, magnesium stearate - 1.5 mg;
• Sheath: macrogol 8000 - 0.2 mg, yellow dye (OY-22906) - 3.1 mg;
• Dye: hypromellose - 1.923 mg, macrogol 400 - 0.192 mg, titanium dioxide - 0.963 mg, dye iron oxide yellow (E172) - 0.022 mg.

Pharmacodynamics and pharmacokinetics

Zomig is a serotoninomimetic of recombinant 5-HT1B receptors located in the walls of cranial vessels. The drug mainly affects 5HT 1B / 1D receptors, moderately affects 5HT 1A receptors and does not affect muscarinic receptors, 5HT 2-, 5HT 4-, A 2-, 5HT 3-, A 1-adrenergic receptors and dopaminergic receptors 1 and 2 types.

Zolmitriptan constricts the blood vessels of the dura mater and slows down the release of vasoactive intestinal peptides, thereby improving the patient's condition during migraine attacks (phonophobia and photophobia disappear, nausea and pain recede).

In addition, Zomig acts on the cells of the brain stem, which are directly involved in the development of migraine attacks. After repeated administration of the drug, a stable anti-migraine effect is observed.

Zolmitriptan is absorbed into the gastrointestinal tract by about 64% of the dose taken, while the absorption of the drug does not depend on food intake. Bioavailability of Zomiga is about 40%. In the process of metabolism, zolmitriptan is converted into a more active N-desmethyl metabolite. Within 60 minutes after taking the drug, the maximum concentration of the active substance is reached, which is maintained for about 5 hours. The half-life is 2.5-3 hours. About 50% of the metabolites are excreted in the urine, about 30% of the active substance is excreted in the feces unchanged.

Indications for use

Zomig is prescribed to relieve migraine attacks with or without aura.

Contraindications

• Transient ischemic attacks or a history of cerebral circulation disorders;
• WPW syndrome or arrhythmias that are associated with other accessory impulse pathways;
• Uncontrolled arterial hypertension;
• Cardiac ischemia;
• Prinzmetal's angina (angiospastic angina);
• Concomitant use with ergotamine or its derivatives or other 5HT1B / 1D-serotonin receptor agonists;
• Hypersensitivity to drug components.

There are no necessary data confirming the safety and efficacy of the drug in patients belonging to the following categories:

• Pregnancy (the appointment of the drug is possible after the doctor evaluates the benefit / risk ratio);
• Lactation period (the drug can be taken with caution);
• Age under 18;
• Old age (the drug can be taken with caution).

Instructions for use Zomig: method and dosage

Zomig is taken orally.

According to the instructions, to stop a migraine attack, Zomig is recommended to be taken in a single dose of 2.5 mg. In cases where symptoms persist or reappear within 24 hours, a second dose can be taken, but not earlier than 2 hours after the first. If necessary, it is possible to double the single dose.

As a rule, the improvement of the condition appears within 1 hour after taking the drug.

The effectiveness of the drug does not depend on how long after the onset of the attack the pill was taken, but it is recommended to take it as early as possible after the onset of the migraine headache.

The total daily dose of Zomiga with the development of repeated migraine attacks should not exceed 10 mg.

Patients with severe functional disorders of the liver are not recommended to exceed the daily dose of 5 mg.

Correction of the dosage regimen for functional disorders of the kidneys is not required.

Side effects

Zomig is generally well tolerated by patients. Side effects are transient, moderate to mild, and usually resolve on their own without therapy.

During the use of Zomiga, the following disorders may occur (≥1% and <10% - often; ≥0.01% and <0.1% - rarely; <0.01% - very rarely):

• Cardiovascular system: rarely - palpitations, tachycardia; very rarely - spasm of coronary vessels, angina pectoris, myocardial infarction, transient arterial hypertension (very rarely accompanied by clinically significant symptoms);
• Digestive system: often - dry mouth, nausea; very rarely - hemorrhagic diarrhea, abdominal pain, spleen infarction, ischemic colitis, intestinal infarction or ischemia;
• Central and peripheral nervous system: often - a feeling of warmth, dizziness, sensitivity disturbances, asthenia, a feeling of stiffness and heaviness in the limbs, tightness in the neck, pharynx and in the chest region (ischemic changes on the electrocardiogram are not accompanied), drowsiness, paresthesia; rarely headache;
• Urinary system: very rarely - frequent urination, polyuria;
• Musculoskeletal system: often - muscle weakness, myalgia;
• Allergic reactions: rarely - angioedema, anaphylactic reactions, urticaria.

Most often, adverse reactions develop within 4 hours after using Zomiga and do not increase with repeated doses.

Overdose

A single dose of the drug in a dose of 50 mg usually has a sedative effect.

The patient should be monitored for at least 15 hours or as long as symptoms of overdose persist. There is no specific antidote for zolmitriptan.

In case of severe poisoning, intensive therapy is carried out, including artificial ventilation of the lungs and maintaining the function of the cardiovascular system. There is no information on the effectiveness of hemodialysis and peritoneal dialysis for serum concentration of zolmitriptan.

special instructions

Zomig should not be used to prevent migraine attacks.

The drug has a pronounced effect on migraines with and without aura, as well as migraines associated with menstruation. Its effectiveness is not affected by: age, gender, duration of the attack, the presence of nausea before taking Zomig and the use of conventional medicines for the prevention of migraine attacks.

Zomig can only be taken after a diagnosis has been made. Other likely serious neurological conditions must be ruled out before starting therapy.

To date, there are no data confirming the efficacy and safety of using the drug for basilar or hemiplegic migraine.

Patients with migraine may have an increased risk of cerebrovascular accident. In patients taking agonists of 5HT1B / 1D-serotonin receptors, subarachnoid, hemorrhagic and ischemic stroke, as well as other disorders of cerebral circulation, were noted.

In very rare cases, when using Zomig, spasms of the coronary vessels, myocardial infarction or angina pectoris occurred. Patients with a high degree of likelihood of developing coronary heart disease are recommended to conduct an examination of the state of the cardiovascular system before starting therapy. In very rare cases, serious complications can occur in patients who did not have a history of indications of diseases of the cardiovascular system.

During therapy, atypical sensations in the heart area may appear. If symptoms of coronary heart disease or chest pain occur, zolmitriptan should be discontinued prior to an appropriate medical examination.

Taking the drug can cause a mild transient increase in blood pressure, regardless of a history of hypertension. In very rare cases, such an increase was clinically significant.

When using Zomig, rare cases of anaphylactoid and / or anaphylactic reactions have been observed.

Excessive use of anti-migraine drugs can lead to an increase in the incidence of headache, which potentially requires discontinuation of therapy.

When driving vehicles and performing potentially hazardous work, it must be borne in mind that the drug can cause negative side effects in the form of drowsiness.

Application during pregnancy and lactation

Clinical studies of Zomiga in pregnant women have not been conducted. Prescribing the drug during pregnancy is possible if the expected benefit to the mother outweighs the potential risk to the fetus.

Experimental studies carried out on animals did not reveal a teratogenic effect of the drug.

During breastfeeding, Zomig is used with caution.

Experimental studies on animals have shown that zolmitriptan is excreted in milk from lactating animals. There is no data on the excretion of the active substance in breast milk in humans.

Pediatric use

There is no information on the effectiveness and safety of the drug in children and adolescents under 18 years of age.

With impaired renal function

In case of impaired renal function, correction of the dosage regimen is not required.

For violations of liver function

In case of mild or moderate liver dysfunction, there is no need to adjust the dose of the drug; in severe liver dysfunction, the maximum dose of the drug should not exceed 5 mg per day.

Use in the elderly

For elderly and senile patients, the drug is prescribed with caution.

Drug interactions

There is no data confirming that concomitant use with drugs for the prevention of migraine (dihydroergotamine, beta-blockers, pizotifen) has any effect on the undesirable effects or effectiveness of Zomiga.

It is necessary to exclude the concomitant use of other 5HT1B / 1D-serotonin receptor agonists within 12 hours after taking Zomig.

With the simultaneous use of Zomiga with some drugs, the following effects may occur:

• Ergotamine: an increase in the likelihood of developing coronary vasospasm (it is recommended to take a break of at least 24 hours between the cancellation of medications containing ergotamine and taking Zomig; after using Zomiga, ergotamine can be taken no earlier than 6 hours later);
• Inhibitors of monoamine oxidase (MAO) type A: an increase in the total concentration of zolmitriptan (the maximum daily recommended dose of Zomiga for patients receiving simultaneously MAO type A inhibitors should not exceed 5 mg);
• Cimetidine: an increase in the total concentration and half-life of zolmitriptan (the maximum daily recommended dose of Zomiga for patients receiving simultaneously cimetidine should not exceed 5 mg);
• Inhibitors of the CYP1A2 isoenzyme: the possibility of interaction (the maximum daily recommended dose of Zomiga for patients receiving simultaneously fluvoxamine and quinolone antibiotics should not exceed 5 mg);
• St. John's wort (Hypericum perforatum): increased risk of unwanted effects.

Analogs

The analogues of Zomig are: Amigrenin, Migrepam, Rapimed, Sumamigren, Sumig, Trimigren, Imigran, Naramig, Relpax, Sumarin, Sumatriptan, Frovamigran, Rapimig, Zolmigren, Zolmitriptan, Zomig Rapimelt.

Terms and conditions of storage

According to the instructions, Zomig should be stored out of the reach of children at temperatures up to 30 ° C.

Shelf life is 2 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Zomiga

Reviews of Zomig on the Internet are positive: the drug is effective against migraine, acts quickly and rarely causes unwanted side effects (the side effects that occur are mild).

Zomig price in pharmacies

The price for a pack of Zomig containing 2 tablets is about 800 rubles.

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!